STOCK TITAN
  1. Home
  2. News
  3. PTGX

Protagonist Therapeutics, Inc - PTGX STOCK NEWS

Welcome to our dedicated page for Protagonist Therapeutics news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics stock.

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs. The company's primary focus is on creating first-in-class oral targeted therapies that inhibit biological pathways currently addressed by injectable antibody drugs. This innovative approach aims to treat significant unmet medical needs, particularly in the areas of inflammatory bowel disease (IBD) and other autoimmune diseases.

Protagonist's lead peptide product candidates, PTG-100 and PTG-200, are designed to transform treatment paradigms for conditions such as ulcerative colitis and Crohn's disease. PTG-100, an oral peptide alpha-4-beta-7 integrin antagonist, is in a global Phase 2b clinical trial for moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral interleukin-23 receptor antagonist, is also progressing through clinical trials.

Another key asset, JNJ-2113 (formerly PN-235), achieved primary and secondary endpoints in the Phase 2b FRONTIER 1 trial for moderate-to-severe plaque psoriasis. This drug is part of an extensive clinical development program, including multiple Phase 3 studies under the ICONIC program. JNJ-2113 is also being evaluated in a Phase 2b ANTHEM-UC study for ulcerative colitis.

Protagonist's pipeline also includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in Phase 3 development for polycythemia vera. The REVIVE Phase 2 study demonstrated that rusfertide effectively maintains hematocrit control and reduces the need for phlebotomies in patients.

The company has established significant partnerships to further its clinical programs. Notably, Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead candidates, expanding its reach and impact in the biopharmaceutical landscape.

Protagonist continues to drive innovation with its ongoing discovery efforts, aiming to develop additional oral peptides targeting validated biological pathways. With a robust pipeline and strategic collaborations, Protagonist Therapeutics is poised to make substantial contributions to the treatment of autoimmune and hematological diseases.

News

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Rhea-AI Summary
Protagonist Therapeutics, Inc. announces the closing of a collaboration and license agreement with Takeda for rusfertide, with a $300 million upfront payment expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
News

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

Rhea-AI Summary
Protagonist Therapeutics, Inc. announced positive results from the Phase 2b FRONTIER 2 study evaluating JNJ-2113 for adult patients with moderate-to-severe plaque psoriasis. The study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, with high rates of skin clearance. The proportion of patients achieving PASI 75, 90, and 100 response rates at Week 16 were maintained through Week 52, confirming the durability of response. No evidence of dose-dependent increase in adverse events was observed across the treatment groups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
-
News

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Protagonist Therapeutics, Inc. announces participation in three upcoming investor conferences in March 2024, including the 2024 Jefferies Biotech on the Bay Summit, 13th Annual Napa Valley Biotech Forum, and H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences
News

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Protagonist Therapeutics (PTGX) announces a collaboration agreement with Takeda Pharmaceuticals, receiving a $300 million upfront payment for rusfertide. The company extended its cash runway through Q4 2027. Significant clinical developments include the Phase 2b study results of JNJ-2113 and rusfertide published in the New England Journal of Medicine. Protagonist achieved $60 million in milestones related to JNJ-2113. Financially, the company reported cash, cash equivalents, and marketable securities of $341.6 million as of December 31, 2023, with license and collaboration revenue of $60 million for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
earnings
-
News

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced positive results from the REVIVE Phase 2 study evaluating rusfertide in polycythemia vera, a rare blood disorder. Rusfertide demonstrated efficacy in maintaining hematocrit levels below 45% without phlebotomy, reducing disease-related symptoms, and improving iron deficiency. The study met primary efficacy endpoints with high statistical significance. The Phase 3 VERIFY trial is ongoing, evaluating rusfertide's efficacy in uncontrolled hematocrit patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
clinical trial
-
News

Protagonist Therapeutics Reports Granting of Inducement Awards

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) issued inducement awards to Vice President Sid Reddy, granting him options to purchase 25,000 shares at an exercise price of $28.23. The shares vest over four years, with 25% vesting on the first anniversary of hire and the rest monthly over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
News

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Rhea-AI Summary
Protagonist Therapeutics, Inc. announced the successful Phase 2b clinical trial of JNJ-2113 in adults with moderate-to-severe plaque psoriasis, achieving primary and secondary endpoints with PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. The study showed a dose-ordered response in patients treated with JNJ-2113, with 79 percent of patients achieving a PASI-75 response at Week 16. The publication in the New England Journal of Medicine (NEJM) reflects the robust efficacy of JNJ-2113, currently being evaluated in multiple Phase 3 psoriasis studies in the ICONIC-program. The study also demonstrated improvements in patient-reported outcomes and a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
clinical trial
-
News

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Rhea-AI Summary
Takeda and Protagonist Therapeutics, Inc. announced a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide for the treatment of Polycythemia Vera. Protagonist will receive a $300 million upfront payment and is eligible for additional milestone payments and royalties. Takeda will lead the ex-U.S. commercialization, while Protagonist will handle U.S. development and regulatory approval. The partnership combines Protagonist's peptide drug development expertise with Takeda's commercial capabilities in rare hematology. The deal aims to address the significant unmet need of PV patients and leverage Takeda's 70-year legacy of innovation in rare diseases. Rusfertide's mechanism of action regulates iron homeostasis and has shown positive results in the Phase 2 trial. The agreement allows Protagonist to focus on Phase 3 completion while sharing profits with Takeda in the U.S. market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.03%
Tags
none
-
News

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

Rhea-AI Summary
Protagonist Therapeutics, Inc. announced that their CEO will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference in New York City on February 7-8, 2024. The presentation will take place on February 8 at 9:00-9:25 A.M. EST at St. Regis New York. A replay of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
conferences
News

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced that its President and CEO, Dinesh V. Patel, Ph.D., will participate in a presentation and host one-on-one meetings with investors at the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024. The presentation will take place on Tuesday, January 9 at 9:45-10:25 A.M. PST in San Francisco, CA. The event details and webcast link can be found on the company's corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
conferences

FAQ

What is the current stock price of Protagonist Therapeutics (PTGX)?

The current stock price of Protagonist Therapeutics (PTGX) is $39.3 as of December 24, 2024.

What is the market cap of Protagonist Therapeutics (PTGX)?

The market cap of Protagonist Therapeutics (PTGX) is approximately 2.3B.

What is Protagonist Therapeutics' main focus?

Protagonist Therapeutics focuses on developing novel peptide-based drugs to address significant unmet medical needs, particularly for inflammatory bowel disease and autoimmune diseases.

What are PTG-100 and PTG-200?

PTG-100 is an oral peptide alpha-4-beta-7 integrin antagonist currently in Phase 2b trials for ulcerative colitis. PTG-200 is a first-in-class oral interleukin-23 receptor antagonist being developed for Crohn's disease.

What is JNJ-2113?

JNJ-2113 (formerly PN-235) is a targeted oral peptide designed to block the IL-23 receptor, currently being evaluated in multiple Phase 3 studies for moderate-to-severe plaque psoriasis and a Phase 2b study for ulcerative colitis.

What is rusfertide (PTG-300)?

Rusfertide is an injectable hepcidin mimetic in Phase 3 development for polycythemia vera. It has shown effectiveness in controlling hematocrit levels and reducing the need for phlebotomies.

Who are Protagonist's collaboration partners?

Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead drug candidates.

What recent achievements has Protagonist announced?

Protagonist reported that JNJ-2113 met all primary and secondary endpoints in the Phase 2b FRONTIER 1 trial and is now in multiple Phase 3 studies. They also entered a significant partnership with Takeda Pharmaceuticals.

What is Protagonist's proprietary technology platform?

Protagonist's proprietary technology platform enables the discovery and development of novel constrained peptide-based drug candidates.

What are the latest developments in Protagonist's clinical trials?

Protagonist has ongoing Phase 3 trials for JNJ-2113 in psoriasis and a Phase 2b trial in ulcerative colitis, as well as a Phase 3 trial for rusfertide in polycythemia vera.

What is the status of the rusfertide Phase 3 VERIFY trial?

The Phase 3 VERIFY trial is nearing completion of enrollment, with top-line data expected by the first quarter of 2025.

Where can I find more information about Protagonist's drug candidates and clinical studies?

More information about Protagonist Therapeutics, its pipeline drug candidates, and clinical studies can be found on the company's website at www.protagonist-inc.com.

Stock PTGX logo
Protagonist Therapeutics, Inc

Nasdaq:PTGX

PTGX Rankings

#1860 Ranked by Market Cap
N/A Ranked by Dividends

PTGX Stock Data

2.34B
57.43M
1.13%
107.25%
5.54%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWARK